While current endpoint-focused amyloid therapies for Alzheimer's disease have proven effective in slowing disease progression, they do not address the underlying cause of neuronal death. Through this project, Drs. Swaney and Krogsæter aim to treat one of the earliest signs of Alzheimer's disease, lysosomal dysfunction, through precise targeting of a novel protein underlying this dysfunction.
